Tobira Therapeutics Inc. (NASDAQ:TBRA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.
According to Zacks, “Tobira Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to treat liver disease, inflammation, liver fibrosis and human immunodeficiency virus. Tobira Therapeutics, Inc., formerly known as Regado Biosciences, Inc., is headquartered in San Francisco, CA. “
TBRA has been the subject of several other reports. Cowen and Company reaffirmed a “buy” rating and set a $11.00 price objective on shares of Tobira Therapeutics in a research note on Wednesday, August 10th. Cantor Fitzgerald began coverage on shares of Tobira Therapeutics in a research note on Wednesday, July 6th. They set a “buy” rating and a $27.00 price objective for the company. Mizuho reaffirmed a “buy” rating and set a $305.00 price objective on shares of Tobira Therapeutics in a research note on Thursday, September 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective (up from $22.00) on shares of Tobira Therapeutics in a research note on Saturday, August 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $68.63.
Tobira Therapeutics (NASDAQ:TBRA) opened at 40.21 on Friday. Tobira Therapeutics has a 52 week low of $3.76 and a 52 week high of $41.39. The company’s market capitalization is $756.79 million. The company has a 50 day moving average of $23.82 and a 200 day moving average of $12.32.
Tobira Therapeutics (NASDAQ:TBRA) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.08. The business had revenue of $1.06 million for the quarter. On average, equities analysts forecast that Tobira Therapeutics will post ($2.65) EPS for the current fiscal year.
In other Tobira Therapeutics news, major shareholder Pentwater Capital Management L acquired 1,624,200 shares of the stock in a transaction that occurred on Thursday, September 22nd. The stock was bought at an average cost of $39.04 per share, with a total value of $63,408,768.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.20% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the company. Havens Advisors LLC acquired a new stake in Tobira Therapeutics during the third quarter worth $119,000. BNP Paribas Arbitrage SA raised its stake in Tobira Therapeutics by 22,003.5% in the third quarter. BNP Paribas Arbitrage SA now owns 75,594 shares of the biopharmaceutical company’s stock worth $3,004,000 after buying an additional 75,252 shares during the period. Schwab Charles Investment Management Inc. acquired a new stake in Tobira Therapeutics during the second quarter worth $177,000. BB Biotech AG acquired a new stake in Tobira Therapeutics during the second quarter worth $5,878,000. Finally, State Street Corp raised its stake in Tobira Therapeutics by 155.5% in the second quarter. State Street Corp now owns 109,527 shares of the biopharmaceutical company’s stock worth $1,377,000 after buying an additional 66,652 shares during the period. 62.02% of the stock is owned by institutional investors.
Tobira Therapeutics Company Profile
Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tobira Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.